We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 3,094

Life sciences: product regulation and liability in China
  • Ropes & Gray LLP
  • China, Global
  • March 15 2018

A structured guide to product regulation and liability laws in China

Bad “Innovator Liability” Decision from the Central District of Illinois in Generic Fluoroquinolone Case
  • Reed Smith LLP
  • USA
  • March 1 2018

We recently read a news story about a man who was imprisoned for 39 years for a crime he did not commit. The crime was grisly and resulted in the

Drug Costs Targeted in Administration’s Fiscal Year 2019 Budget
  • Cooley LLP
  • USA
  • February 13 2018

Yesterday, the Administration released its Fiscal Year 2019 (FY19) Budget blueprint. The $4.4 trillion Budget blueprint includes several proposals

FY 2019 President’s Budget - Health Care
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 12 2018

Today, the White House released its FY 2019 budget proposal, outlining its policy priorities for the fiscal year. This is the first real budget of the

The State AG Weekly Update February 8, 2018
  • Cozen O'Connor
  • USA
  • February 8 2018

North Dakota AG Wayne Stenehjem declared his intention to run for reelection to a sixth term in 2018. Prior to taking office as AG in 2000, AG Ste

PMPRB releases report analyzing generic drug pricing in Canada
  • Smart & Biggar/Fetherstonhaugh
  • Switzerland, United Kingdom, Canada, France, Germany, Italy
  • February 6 2018

On February 6, 2018, the Patented Medicine Prices Review Board (PMPRB) announced the publication of the most recent edition of its series of

Formulation patents may prevent reimbursement of generics but, are you innovative enough?
  • Hogan Lovells
  • Italy
  • January 31 2018

The possibility for the patent owner to prevent the reimbursement of medicinal products before expiry of patent protection is still an open issue

FDA’s Proposed New Pathway for Devices Referencing Drugs (DRDs)
  • Hogan Lovells
  • USA
  • January 19 2018

The Food and Drug Administration (FDA) may be closing in on solving one of its perennial regulatory problems, namely, the absence of a workable

Generic drugs taking hold in the Asian marketplace: STAT News interview
  • Hogan Lovells
  • Japan
  • January 18 2018

Aging populations and rising healthcare costs across Asia particularly in Japan have created new market opportunities for generic drug makers

Still No “Newly Acquired Information,” Eliquis Claims Still Preempted
  • Reed Smith LLP
  • USA
  • December 6 2017

The defendants in the Eliquis MDL have turned somewhat of a preemption hat trick. The latest order is In re Eliquis (Apixaban) Prods. Liab. Litig